Feb 4 2010
Morningside Technology Ventures, Prism VentureWorks, and Ivy Capital
Partners are pleased to announce the acquisition of their portfolio
company, Serica Technologies, Inc. by Allergan, Inc. Serica is a
growth-stage medical device company focused on the development of
biodegradable silk-based scaffolds for use in tissue regeneration in
numerous therapeutic areas. Following the acquisition, Serica became a
wholly owned subsidiary of Allergan. Serica Stockholders received an
upfront cash payment plus equity in a new company, Alacer Biomedical,
Inc., which holds exclusive rights to Serica’s intellectual property
within orthopedic and veterinary indications. The value of the
transaction was not disclosed.
“This highly successful outcome was made possible by both an outstanding
technology and a top-notch team”
Serica was formed in 1998 based on technology originating from Tufts
University. Prior to the acquisition, Serica had raised less than $24M
in equity financing from a syndicate that included Morningside, Prism,
Ivy, and various individual investors. Allergan plans to continue
operating Serica out of Serica’s state-of-the-art office, R&D, and
manufacturing facility in Medford, MA.
“I am exceptionally pleased about this outcome for all of Serica’s
shareholders,” said Gregory H. Altman, Ph.D., CEO and Founder of Serica.
“Our dedicated team created a truly revolutionary biomaterial platform
and then demonstrated its utility in a number of medical indications.
Given Allergan’s expertise across multiple health care specialties, they
were able to quickly gauge the great potential of our technology
platform. Our team is excited to join Allergan Medical and we are
further motivated by their strong commitment to continue developing
Serica’s technology. I am also very pleased that Alacer will continue
developing Serica’s scaffold platform within orthopedics and veterinary
medicine where great unmet clinical needs still exist.”
“This highly successful outcome was made possible by both an outstanding
technology and a top-notch team,” commented Brendan M. O’Leary, Ph.D.,
General Partner at Prism. “We began exploring strategic partnerships
last summer with a number of industry players which very quickly led to
acquisition discussions. Many large medical device companies have
weathered the storm and now have shifted focus to future growth. Serica
provided a unique opportunity to tap into huge new markets with a
revolutionary technology and to acquire a small, highly productive R&D
team with unique skill sets around that technology. It was a difficult
decision to sell Serica, but the Allergan transaction provided the
shareholders with an excellent return while maintaining the ability to
hold onto several high value indications within the Alacer spin-off.”
“As Serica’s first institutional investor, Morningside was attracted by
its novel technology and Greg’s vision. We are pleased to have worked
with Greg and the Serica team to achieve this success for the employees
and investors,” noted Stephanie Monaghan O’Brien of Morningside. “We are
excited about Alacer’s goals for this technology in orthopedic and
veterinary indications.”
Robert W. Pangia, Principal at Ivy Capital Partners, stated, “The
transaction with Allergan is an endorsement of the clinical and
commercial value of Serica’s novel silk-based scaffold technology. This
exit represents an excellent return for Ivy’s investors and we are
pleased to have had an opportunity to partner with Serica’s creative and
dynamic management team. We look forward to continuing both the
underlying technology development and pattern of success with Alacer.”
Source:
Morningside Technology Ventures, Prism VentureWorks and Ivy Capital Partners